This page was printed from the Northern & Eastern Devon Formulary and Referral site at
Please ensure you are using the current version of this document
See Contraception Guidance for advice on
In the absence of any other clinical reason, the product of lower acquisition cost should be chosen
Evidence suggests that CHCs containing the 'third generation' progestogens gestodene or desogestrel are associated with an increased risk of venous thromboembolism (VTE) when compared with those containing the 'second generation' progestogens levonorgestrel or norethisterone.
CHC containing a 3rd generation progestogen may be suitable for women who experience unacceptable side-effects from other progestogens. It is important that the woman is aware of the possible increased risk of venous thromboembolism, backed up with an up-to-date leaflet. The Family Planning Association produce a suitable leaflet (The Combined Pill).
Home > Formulary > Chapters > 7. Obstetrics, gynaecology, and urinary-tract disorders > 7.3 Contraceptives > 7.3.1 Combined hormonal contraceptives (CHC)